Clinical Trial Update: Phase 2 Study of Rituximab-ABVD in Classical Hodgkin Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 study update for Rituximab-ABVD in classical Hodgkin lymphoma has completed recruitment with results posted in 2015.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Classical Hodgkin Lymphoma
• Hodgkin Lymphoma

Drugs mentioned

• Rituximab-ABVD (rituximab-ABVD)

Snippet

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Conditions: Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2015-07-03